Intravenous immunoglobulin therapy for resistant ocular Behçet's disease.
OBJECTIVE
The present report was aimed at finding out whether gammaglobulin could have a role in treating ocular Behçet's disease (BD) refractory to accepted medical therapy.


METHODS
Six eyes of four patients with ocular BD refractory to steroids and cyclosporin A were treated with a course of intravenous gammaglobulin and followed up for their response to treatment.


RESULTS
All six eyes of all four patients showed good response to gammaglobulin therapy.


CONCLUSIONS
Gamma globulin may have a role in treating refractory ocular BD. A wide range of controlled studies with longer follow up is needed to substantiate this impression.
Seider
N
N
Department of Ophthalmology, Rambam Medical Center, POB 9602, 31096 Haifa, Israel.
Beiran
I
I
Scharf
J
J
Miller
B
B
D000293:Adolescent; D000328:Adult; D001528:Behcet Syndrome / Q000150:complications / Q000628:therapy*; D016572:Cyclosporine / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015864:Panuveitis / Q000209:etiology / Q000628:therapy*; D017211:Treatment Failure; D016896:Treatment Outcome
D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D016572:Cyclosporine